TWD 70.8
(0.28%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 54.43 Million TWD | 320.31% |
2022 | 12.95 Million TWD | 111.85% |
2021 | -109.27 Million TWD | 41.87% |
2020 | -187.98 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | 38.18 Million TWD | -33.07% |
2024 Q1 | 57.05 Million TWD | 4.82% |
2023 Q2 | 19.73 Million TWD | 0.0% |
2023 FY | 54.43 Million TWD | 320.31% |
2023 Q4 | 54.43 Million TWD | 373.55% |
2023 Q3 | -19.89 Million TWD | -200.82% |
2023 Q1 | - TWD | -100.0% |
2022 FY | 12.95 Million TWD | 111.85% |
2022 Q4 | 12.95 Million TWD | 0.0% |
2021 FY | -109.27 Million TWD | 41.87% |
2020 FY | -187.98 Million TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Apex Biotechnology Corp. | -201.21 Million TWD | 127.051% |
Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | 93.747% |
Panion & Bf Biotech Inc. | 193.2 Million TWD | 71.828% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 94.207% |
GenMont Biotech Incorporation | 2.71 Million TWD | -1907.006% |
Abnova (Taiwan) Corporation | -415.8 Million TWD | 113.09% |
Adimmune Corporation | 685.12 Million TWD | 92.056% |
Tanvex BioPharma, Inc. | 1.35 Billion TWD | 95.971% |
Polaris Group | -2.41 Billion TWD | 102.25% |
Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 122.071% |
PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | -1015.14% |